Chemotherapeutic targeting of myeloid-derived suppressor cells

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Myeloid-derived suppressor cells (MDSCs), which expand in cancer-bearing hosts, contribute to the escape of malignant cells from immune destruction and impair the efficacy of immunotherapeutic interventions. We have recently demonstrated that the conventional chemotherapeutic agent doxorubicin selectively eliminates MDSCs, hence promoting the activity of immune effector cells and improving the therapeutic profile of adoptively transferred helper T lymphocytes.

Original languageEnglish (US)
Article numbere27338
JournalOncoImmunology
Volume3
Issue number1
DOIs
StatePublished - 2014

Fingerprint

Helper-Inducer T-Lymphocytes
Doxorubicin
Neoplasms
Myeloid-Derived Suppressor Cells
Therapeutics

Keywords

  • Cancer
  • Chemoimmunomodulation
  • Doxorubicin
  • Helper T lymphocytes
  • Myeloid-derived suppressor cells
  • ROS

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

Chemotherapeutic targeting of myeloid-derived suppressor cells. / Alizadeh, Darya; Katsanis, Emmanuel; Larmonier, Nicolas.

In: OncoImmunology, Vol. 3, No. 1, e27338, 2014.

Research output: Contribution to journalArticle

@article{76e40a71c23d4daf9e63d4349cfe85b9,
title = "Chemotherapeutic targeting of myeloid-derived suppressor cells",
abstract = "Myeloid-derived suppressor cells (MDSCs), which expand in cancer-bearing hosts, contribute to the escape of malignant cells from immune destruction and impair the efficacy of immunotherapeutic interventions. We have recently demonstrated that the conventional chemotherapeutic agent doxorubicin selectively eliminates MDSCs, hence promoting the activity of immune effector cells and improving the therapeutic profile of adoptively transferred helper T lymphocytes.",
keywords = "Cancer, Chemoimmunomodulation, Doxorubicin, Helper T lymphocytes, Myeloid-derived suppressor cells, ROS",
author = "Darya Alizadeh and Emmanuel Katsanis and Nicolas Larmonier",
year = "2014",
doi = "10.4161/onci.27359",
language = "English (US)",
volume = "3",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "1",

}

TY - JOUR

T1 - Chemotherapeutic targeting of myeloid-derived suppressor cells

AU - Alizadeh, Darya

AU - Katsanis, Emmanuel

AU - Larmonier, Nicolas

PY - 2014

Y1 - 2014

N2 - Myeloid-derived suppressor cells (MDSCs), which expand in cancer-bearing hosts, contribute to the escape of malignant cells from immune destruction and impair the efficacy of immunotherapeutic interventions. We have recently demonstrated that the conventional chemotherapeutic agent doxorubicin selectively eliminates MDSCs, hence promoting the activity of immune effector cells and improving the therapeutic profile of adoptively transferred helper T lymphocytes.

AB - Myeloid-derived suppressor cells (MDSCs), which expand in cancer-bearing hosts, contribute to the escape of malignant cells from immune destruction and impair the efficacy of immunotherapeutic interventions. We have recently demonstrated that the conventional chemotherapeutic agent doxorubicin selectively eliminates MDSCs, hence promoting the activity of immune effector cells and improving the therapeutic profile of adoptively transferred helper T lymphocytes.

KW - Cancer

KW - Chemoimmunomodulation

KW - Doxorubicin

KW - Helper T lymphocytes

KW - Myeloid-derived suppressor cells

KW - ROS

UR - http://www.scopus.com/inward/record.url?scp=84899061598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899061598&partnerID=8YFLogxK

U2 - 10.4161/onci.27359

DO - 10.4161/onci.27359

M3 - Article

AN - SCOPUS:84899061598

VL - 3

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 1

M1 - e27338

ER -